Pay in 4 interest-free payments of $6.64 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Eligibility is limited to legitimate clinical-trial criteria until regulators approve an indication
The gastrointestinal side effects are consistent with GLP-1 receptor activation and are generally manageable with appropriate dosing strategies and patient education
Tirzepatide (Zepbound) for the treatment of obesity
These effects are part of why treatment may help some patients feel full sooner and reduce food noise
Efficacy: Semaglutide has superior reductions in HbA1c and body weight compared to other agents, while tirzepatide, a dual GLP-1/GIP receptor agonist, shows even greater efficacy but with higher rates of adverse events
.webp)
US$ 22.15
US$ 27.02
US$ 20.28
US$ 26.69
